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Abstract
The development of a new drug requires research and evaluation before the drug is approved to enter the market. One of the
IDFWRUVGHWHUPLQLQJWKHHIÀFDF\RIDGUXJLVWKHDTXHRXVVROXELOLW\RIWKHGUXJ$FXUUHQWSUREOHPLQWRGD\·VSKDUPDFHXWLFDO
industry is the low aqueous solubility of many useful drugs. A drug with a low aqueous solubility will not readily be absorbed by
WKHERG\7KHORZDTXHRXVVROXELOLW\RIDGUXJLVRIWHQGXHWRWKHGUXJ·VK\GURSKRELFFKDUDFWHU'UXJHQKDQFHPHQWPHWKRGVDUH
necessary to avoid the obstacle of drug insolubility and many methods have been developed. This paper focuses on the use of
F\FORGH[WULQVDQGWKHLUGHULYDWLYHVDVDGUXJFDUULHUWRLQFUHDVHWKHVROXELOLW\RISRRUO\VROXEOHGUXJV &\FORGH[WULQVKDYHERWK
hydrophobic and hydrophilic character and are capable of encapsulating a hydrophobic drug molecule and forming guest-host
FRPSOH[HV7KHF\FORGH[WULQ·VF\OLQGULFDOVKDSHDOORZVWKHJXHVWPROHFXOH WKHGUXJ WREHNHSWZLWKLQWKHK\GURSKRELFLQWHULRU
ZKLOHWKHH[WHULRURIWKHF\FORGH[WULQLVK\GURSKLOLFDQGVROXEOHLQDTXHRXVVROXWLRQ7KLVFRPSOH[LPSURYHVWKHGUXJVROXELOLW\
DQGXOWLPDWHO\WKHELRDYDLODELOLW\RILQVROXEOHGUXJV ,QWKLVSDSHUWKHFRPSOH[DWLRQRIIRXUGUXJVZLWKF\FORGH[WULQZDVVWXGLHG
ibuprofen, imatinib, praziquantel and camptothecin. In each case the aqueous solubility of the poorly soluble drug was increased
ZLWKWKHXVHRIF\FORGH[WULQV
Introduction
The development of a drug is a process of converting a biologically active compound into a product that is safe and effective, it
is a long and expensive process. The performance of a drug, the
HIÀFLHQF\RIWKHGUXJLQFDUU\LQJRXWWKHGHVLUHGDFWLRQLVGHSHQdent on the drug’s properties. Chemical and physical properties
of a drug determine the drug’s ability to react with the necessary
components along the path to achieving the desired effect. One
of the factors determining a drug’s performance and effectiveness
is the aqueous solubility of the drug (Gareth, 2007).

Solubility of a Compound
,83$& GHÀQHV VROXELOLW\ DV WKH FRPSRVLWLRQ RI D VDWXUDWHG
solution in terms of the amount of solute in proportion to
solvent (McNaught, Wilkinson, 2006). Solubility is the term
used to describe a solid, liquid, or a gas’s ability to dissolve in
a solvent. Aqueous solubility of a molecule changes depending
on the electrostatic charge of the molecule and the degree of
ionization. The dipoles in the water molecules are attracted to
the charged molecules forming a shell around the molecule and
solvating it (Trevor et.al. 2015).
Solubility of a compound depends also on its structure and
polarity. Polar groups can hydrogen bond with water molecules
and be solvated, nonpolar groups are insoluble in aqueous solution. Therefore, the aqueous solubility of a compound increases
as the number of polar groups on the compound increases. In
addition, if the polar groups on a compound have the ability to
ionize in water, the compound will be further soluble. Lipid soluble compounds are those with more nonpolar groups and they
may contain functional groups such as benzene rings, ethers and
esters. Amphipathic compounds with polar and non-polar parts
are soluble in both aqueous and lipid solvents (Gareth, 2007).

Drug Solubility
Solubility is a fundamental property that must be considered
when evaluating a drug. The solubility of a drug can range from
fully soluble, like ethanol in water, to poorly soluble, often referred
to as insoluble (Clugston, Fleming, 2000). The Biopharmaceutics
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&ODVVLÀFDWLRQ 6\VWHP %&6  LV D JXLGH IURP WKH 86 )RRG DQG
Drug Administration and is used to regulate and classify drugs
based on aqueous solubility and membrane permeability. Class
I drugs have high aqueous solubility and high membrane permeability, Class II drugs have low aqueous solubility and high membrane permeability, Class III have high aqueous solubility and low
membrane permeability, and Class IV drugs have low aqueous
solubility and low membrane permeability. Solubility of a drug is
determined based on the drug’s solubility over a pH range of 1 to
7.5 and is considered very soluble if the highest dose strength is
soluble in <250 ml of water.The membrane permeability of a drug
is measured by the extent of absorption and a drug is considered
highly permeable when the absorption in humans is > 90% of an
administered dose (FDA, BCS, 2016). Since cells typically contain
65% water, a drug must be water soluble to be effective. A drug
must be absorbed before entering the bloodstream in order for
the drug to be transported via the systemic circulation to its site
of action. The more soluble the drug the greater amount of absorbed drug in the bloodstream. More drug in the bloodstream
increases the gradient between the bloodstream and the extraFHOOXODUÁXLGLQWKLVZD\GLIIXVLRQRIWKHGUXJIURPWKHEORRGWR
WKH H[WUDFHOOXODU ÁXLG ZLOO EH IDFLOLWDWHG 7UHYRU HW DO   ,Q
addition, the more water soluble the drug the higher the bioavailability (Gareth, 2007).The amount of drug that is absorbed by the
bloodstream, divided by the amount that was administered, is the
ELRDYDLODELOLW\RIWKDWGUXJDGPLQLVWHUHGLQWKDWVSHFLÀFPDQQHU
Drug absorbed / drug administered = bioavailability of the drug
(Trevor et. al. 2015).
Oral drugs are the most common form of drug administration.
7KH\DUHHDV\WRDGPLQLVWHUDUHOHVVVSHFLÀFLQWKHLUVWHULOLW\UHquirements, they are most cost effective, have a high patient comSOLDQFHDQGWKHUHLVÁH[LELOLW\LQWKHGRVDJHIRUP)RUWKLVUHDVRQ
many pharmaceutical companies prefer to produce bioequivalent
RUDOGUXJV7KHGLIÀFXOW\ZLWKRUDOELRHTXLYDOHQWGUXJVLVWKHLUORZ
aqueous solubility and therefore low bioavailability. Oral drugs
PXVW ÀUVW GLVVROYH LQ WKH DTXHRXV JDVWULF ÁXLG LQ RUGHU WR EH
transported to the site of action.Therefore, solubility of a drug is
an important factor in determining the concentration of a drug
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that is required to achieve a desired response. More than 40% of
pharmaceutical developments are poorly soluble in water. Low
solubility of a drug slows the absorption rate, decreasing the bioavailability. Thus, solubility enhancement methods are necessary.
Increasing a drug’s solubility is a challenge faced by the drug development industry, especially the solubility of oral drugs (Savjani
et. al. 2012). Increasing the solubility of Class II drugs that have
low solubility and high permeability would be very productive.
The rate limiting step for Class II drugs, according to the BCS, is
the insolubility of the drug, therefore increasing the solubility will
increase the bioavailability of those drugs.
There are many methods that are currently used to increase
the solubility of new chemical entities (NCE’s). There are physLFDO DQG FKHPLFDO PRGLÀFDWLRQV WKDW FDQ EH PDGH WR D GUXJ WR
increase its solubility. Particle size reduction can be employed, as
well as solid dispersion, nanosuspension, colloidal particles, and
changes to the crystal form. Additionally, chemical changes to pH
as well as complexation and salt formation affect the solubility
(Savjani et. al. 2012).
Other methods include the use of surfactants, micelles, liposomes and inclusion complexes (Gareth, 2007). These methods
utilize the hydrophobic effect in increasing the solubility of a molecule. Cyclodextrins and cyclodextrin derivatives form inclusion
complexes with insoluble drugs. Inclusion complexes apply guesthost chemistry in the formation of the complex. This paper will
focus on cyclodextrins and cyclodextrin derivatives as a method
to increase the solubility of a poorly soluble drug.

of six, seven, or eight glucose units.The cyclodextrin ring form is
composed of њ-D-glucopyranoside units with 1ĺ4 linkage like
in amylose (Gareth, 2007). When glucose is degraded by the enzyme glucosyltransferase, a product of the chain splitting can undergo an intramolecular reaction to form cyclic molecules, cyclodextrins. Each glucose molecule in the cyclodextrin contains
two secondary alcohols and a primary alcohol. Alpha (њ), beta
(ћ), or gamma (ќ) cyclodextrins, depending on whether they
contain six, seven, or eight glycosyl units respectively, are classiÀHGDVQDWXUDOF\FORGH[WULQV&KHPLFDOO\GHULYHGF\FORGH[WULQV
are hydroxypropyl-ћ-cyclodextrin, randomly methylated-ћ-cyclodextrin, and sulfobutylether-ћ-cyclodextrin. These derivatives are often preferred due to their enhanced physiochemical
and biopharmaceutical properties (Gidwani,Vyas, 2015).

Cyclodextrin Synthesis
B. macerans is the microbe responsible for the formation of
cyclodextrins. A method to synthesize cyclodextrins is to treat
starch with amylase from Bacillus macerans. A crude product
of cyclodextrin is then obtained with about 60% њCD, 20%
ћCD, and 20% ќCD. The product also contains small amounts
of other materials including proteins. To purify the different

Methods
This study was completed by analyzing various articles collected from databases including Touro Library and PubMed. The research collected mainly explored cyclodextrins and their ability
to form guest-host complexes.

Discussion:
Cyclodextrin and Cyclodextrin Derivatives
Cyclodextrins (CD’s), and their derivatives are amphipathic molecules capable of forming guest-host complexes with drug molecules. The complex improves the drug solubility and ultimately
the bioavailability of insoluble drugs. Cyclodextrins are used as a
drug delivery system because of their potential to change physical, chemical and biological properties of a drug by forming a
guest-host complex (Gareth, 2007). From a microscopial point
of view, each guest molecule is micro-encapsulated leading to
changes in the chemical and physical properties of the molecule.
Cyclodextrins and their derivatives can improve the solubility of
a molecule, modify a liquid substance to a powder, and mask a bad
taste, smell or color of a drug (Chaudhary, Patel, 2013).

Cyclodextrin Structure
Cyclodextrins are cylindrical oligosaccharides typically made up

)LJXUH&\FORGH[WULQ6WUXFWXUH %UHZVWHU/RIWVVRQ

)LJXUH7RS²ERWWRPњ, ћ, ќ&'GHULYDWLYHV *LGZDQL9\DV
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cyclodextrin derivatives, various forms of glucosyltransferases
are genetically engineered.These glucosyltransferases are active
WRZDUGVWKHSURGXFWLRQRIVSHFLÀFF\FORGH[WULQGHULYDWLYHV7KH
glucosyltransferase enzymes distinguish the six, seven, or eight
glucopyranose units from the non-reducing end of an amylose
DQGDOWHUWKHOLQNDJHWRSURGXFHDVSHFLÀFF\FORGH[WULQGHULYDtive (Brewster, Loftsson, 2007).

Hydropathy of Cyclodextrin
Cyclodextrins are amphipathic molecules. They have hydrophobic and hydrophilic character. Cyclodextrins have a hydrophobic interior and hydrophilic exterior. The polar exterior of the
cyclodextrin forms hydrogen bonds with the aqueous solution.
The hydrophobic effect drives the non-polar portion of the cyclodextrin inwards, away from the aqueous solution, forming a
hydrophobic cavity. This property enables the cyclodextrin to
form guest-host inclusion complexes with hydrophobic molecules (Chaudhary, Patel, 2013).
Cyclodextrins can encapsulate many molecules. The nonpolar hydrophobic molecule interacts with the nonpolar groups
in the interior of the cyclodextrin, while the polar hydroxyl
groups on the exterior surface of the cyclodextrin are hydrophilic. Hydrophobic molecules the size of one or two benzene
ULQJV FDQ ÀW LQWR WKH F\FORGH[WULQ FDYLW\7KH F\FORGH[WULQV LQ
the complex increase the aqueous solubility of the guest molecule, often a drug. The interactions between the cyclodextrin
and the drug form the inclusion complex, the cyclodextrin host
molecule with the guest drug (Tiwari et. al. 2010).

Cyclodextrin-Drug Complex
A number of forces are responsible for the complex formation;
hydrogen bonding, van der Waals interactions, release of conformational strain, and exclusion of high energy water bonds
in the cyclodextrin cavity. Thermodynamic interactions are the
main drive in the formation of the cyclodextrin-guest complex.
Thermodynamically, the interaction between the cyclodextrin
host, the guest molecule, and the solvent, must overall be favorable in order for the reaction to proceed (Chaudhary, Patel,
2013). The cyclodextrin complex formation is usually enthalpy
driven. In an aqueous solution the cyclodextrin cavity contains
polar water molecules that are readily exchanged for non-polar hydrophobic guest molecules. The water molecules situated
inside the non-polar environment of the cyclodextrin cavity do
not have a full complement of hydrogen bonds and are higher
in energy than the water molecules outside the cyclodextrin.
Liberating the water molecules that are enthalpy-rich, high in
energy, is a driving force for the complexation. Sterically, the
size and certain functional groups of the guest molecule deterPLQHWKHDELOLW\RIWKHJXHVWWRÀWLQWRWKHF\FORGH[WULQFDYLW\
Additionally, the complex formation is dependent on the chemical properties of the guest molecule (Brewster, Loftsson, 2007).
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The formation of the cyclodextrin-drug complex can be
achieved through several methods. The kneading method is
a simple and inexpensive method and is therefore the most
commonly used method for preparing the complex (Savjani et.
al. 2012). This method converts the cyclodextrin into a paste
by saturating the cyclodextrin or cyclodextrin derivative with
water or hydroalcoholic solution. The drug is then added to the
paste and the mixture is kneaded. The kneading can be done either in the laboratory or using machines for large scale achievement of the complex. An additional method, the lyophilization/
freeze-drying technique, works with a solution of cyclodextrin
and drug. The solvent in the solution is removed by freezing the
solution and then drying it by rapidly reducing the pressure,
generating a powder. The increased surface area of the powder
enables considerable interactions between the cyclodextrin and
the drug (Savjani et. al. 2012).
Cyclodextrins can increase the solubility of the guest molecule in three patterns when graphed with cyclodextrin conFHQWUDWLRQ DQG GUXJ VROXELOLW\$/ SURÀOHV LQGLFDWH D OLQHDU LQcrease in drug solubility as the concentration of cyclodextrin
is increased. AP systems have a curve that deviates in a positive
direction from the linearity indicating that the cyclodextrin is
proportionally more effective at higher concentrations. AN
relationships have a negative deviation from the linearity indicating that at higher concentrations cyclodextrin’s effectiveness
decreases (Brewster, Loftsson, 2007).

Complex Dissociation
Once a product of drug-cyclodextrin is obtained, the complex
must dissociate to release free drug upon reaching the site of
action.When drug is encapsulated within the cyclodextrin there
are factors that cause the complex to dissociate and release
free drug. The drug and cyclodextrin interactions are non-covalent interactions that are in dynamic equilibrium, constantly
associating and dissociating. There are two important factors
FRQFHUQLQJWKHFRPSOH[·VQRQFRYDOHQWLQWHUDFWLRQVÀUVWO\WKH
FRPSOH[DWLRQVWUHQJWKGHÀQHGE\.DQGVHFRQGO\WKHFRPSOH[
lifetime. In a 1:1 complex ratio of drug to cyclodextrin the comSOH[DWLRQVWUHQJWKWKH.FRQVWDQWLVGHÀQHGE\WKHHTXDWLRQ
K = kf / kt = [DCyD] / [Df] [CyDf] where kf and kt are the
forward and reverse rate constants, [DCyD] is the complex
concentration and [Df] and [CyDf] are free drug and free cyclodextrin respectively.
Dilution is a major factor assumed to play a role in the dissociation of the complex. 1000-fold dilution of a drug with a low
binding constant to cyclodextrin decreased the complexation
percentage from 98% to 5.7%. The fraction of complexed drug
decreased from 99.5% to 47.5% in the presence of 1000-fold
dilution of a drug with a high binding constant to cyclodextrin.
Therapeutically, the complexed drug is diluted either
LQ WKH SODVPD RU LQ WKH DTXHRXV H[WUDFHOOXODU ÁXLG$ P/
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drug-cyclodextrin complex administered via intravenous injection is diluted in the plasma by a factor of 1:3,500, in the
H[WUDFHOOXODUÁXLGWKHIDFWRULV'LOXWLRQDORQHLVQRW
VXIÀFLHQW LQ RUDOO\ DGPLQLVWHUHG GUXJV EHFDXVH WKH FRPSOH[
resides in the gastrointestinal tract before reaching the site
of action.
Drug binding to plasma protein is another factor responsible
for complex dissociation. If a drug has the ability to bind to
plasma protein the complex would dissociate further to release
more free drug according to Le Chatelier’s principle. Drugs with
a high binding constant to cyclodextrin that have the ability to
bind moderately to proteins, in 1000-fold dilution, are further
dissociated and only 31.9% complexed drug remains. If the drug
binds more tightly to proteins the factor of complexed drug
decreases to 8.9%.
Furthermore, if a drug is lipophilic and can be taken up by tissue
more drug would be released from the complex.The cyclodextrin
would remain in the aqueous solution and drug would be taken up
by tissue. This mechanism is especially useful in drug administered
DWDVLWHWKDWKDVLQVLJQLÀFDQWGLOXWLRQ 6WHOODHWDO 
The dissociation process is driven mainly by an increase of
water molecules in the surrounding environment and happens
relatively fast. In a dilute environment there is a concentration
gradient which shifts the equilibrium to the left, dissociating the
cyclodextrin and the drug, thereby releasing free drug to be
absorbed. In the body’s dynamic environment, it is not likely
that the drug will encounter another cyclodextrin with which
to form a complex and in this way it remains free in the solution
(Chaudhary, Patel, 2013).

Complexed Drug Pharmacokinetics
The effect of cyclodextrins on the pharmacokinetics of complexed drug must be considered before cyclodextrin complexation can be applied. Kurkov et. al. studied the effect of complexation on the pharmacokinetics of close to 200 drugs. The
results concluded that the hydroxypropyl-ћ-cyclodextrin does
QRW KDYH D VLJQLÀFDQW HIIHFW RQ WKH SKDUPDFRNLQHWLFV RI WKH
drugs. However, although not altered, some drug is lost due to
the complexation. The hydrophilic cyclodextrins are excreted
unchanged by the kidneys and any drug still encapsulated is
excreted too. This is especially true when the drug has a high
binding constant to cyclodextrin (Kurkov et. al. 2012).

Toxicological Considerations
2UDOO\ DGPLQLVWHUHG F\FORGH[WULQV DUH QRW VLJQLÀFDQWO\ DEsorbed in their intact form from the gastrointestinal tract. The
Cyclodextrins range from 1000 Da to over 2000 Da in molecuODUZHLJKWDQGDUHK\GURSKLOLFZLWKVLJQLÀFDQWK\GURJHQERQGLQJ
donors and acceptors, therefore they cannot be absorbed in
their original form. Natural њ-cyclodextrin and ћ-cyclodextrin cannot be hydrolyzed by human salivary and pancreatic

amylases and in general oral administration is not associated
ZLWK VLJQLÀFDQW DGYHUVH HIIHFWV DQG LV ZHOO WROHUDWHG$IWHU ,9
injection њ-cyclodextrin is mainly excreted unchanged in the
urine. ћ-cyclodextrin is nephrotoxic when administered parenterally but non-toxic in the topical, buccal, rectal or oral form
and can be found in numerous marketed drugs. The metabolism
of ќ-cyclodextrin is similar to that of starch and linear dextrins
and only small amounts are absorbed intact. After iv injection
the ќ-cyclodextrin is mainly excreted unchanged in the urine
(Brewster, Loftsson, 2007).

Ibuprofen-Cyclodextrin

,EXSURIHQ LV D QRQVWHURLGDO DQWLLQÁDPPDWRU\ GUXJ 16$,' 
used to treat mild to moderate pain and fever. Ibuprofen works
by inhibiting cyclooxygenase, an enzyme that converts arachidonic acid to cyclic endoperoxides. Cyclic endoperoxides are
SUHFXUVRUV WR SURVWDJODQGLQV UHVSRQVLEOH IRU LQÁDPPDWLRQ
(PubChem, 2004).
Ibuprofen is a poorly water soluble drug. Although it contains
a carboxylic acid functional group which can hydrogen bond
with water and be solvated, the alkyl groups and the benzene
ring are non-polar and make the drug poorly soluble. Ibuprofen
is complexed with cyclodextrin derivatives to increase its solubility (Hussein et. al. 2007).
Khaled Hussein, et al. conducted a study on the ibuprofen-ћ-cyclodextrin complex (Hussein et. al. 2007). A solid
complex of ibuprofen, MW 206.3 g/mol, and ћ-cyclodextrin,
MW 1,135.0 g/mol, was prepared. Using controlled Particle
Deposition (CPD) with supercritical carbon dioxide the ibuprofen-ћ-cyclodextrin complex was formed.The CPD method
dissolves the desired solution in supercritical carbon dioxide
which then enters the pores of the carrier at extremely high
pressure and precipitates following a rapid pressure drop.
The “n-hexane wash” method determined whether the complex was formed. ћ-cyclodextrin and its complexes are insoluble in n-hexane but the free drug is soluble. The supernatant
liquid that was insoluble was separated, dried and then analyzed
by high-performance liquid chromatography (HPLC). HPLC determined the product yield as well as the content of ibuprofen
in the complex. The inclusion yield of the complex was determined using the following equation:
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Percent of included ibuprofen= [complexed amount
of ibuprofen/free amount + complexed amount] x 100
49.83±3.65 inclusion yield % was calculated.
Infrared spectroscopy of pure ibuprofen showed all the
characteristic peaks including the carbonyl peak at 1,706 cm-1.
The complexed drug’s infrared spectroscopy had a very week
carbonyl peak indicating that the drug molecule was encapsulated inside the ћ-cyclodextrin. Morphological changes were
also observed. Pure ibuprofen is rough needle-shaped crystals
and ћ-cyclodextrin is parallelogram shaped. The shape of the
complexed particles appeared smaller in size and different than
pure drug or pure ћ-cyclodextrin. This observation adds to the
evidence of the ibuprofen-ћ-cyclodextrin complex formation.
7KH FRPSOH[ ZDV WHVWHG IRU GUXJ UHOHDVH XVLQJ D ÁRZ V\Vtem with a dissolution vessel at pH 5 and 37°C. A sample of
pure ibuprofen and a sample of complexed ibuprofen, each
containing 3mg ibuprofen, were added to the vessel. Samples
ZHUHWDNHQIURPWKHGLVVROXWLRQÁXLGDWVHWLQWHUYDOVDQGZHUH
VWXGLHGVSHFWURSKRWRPHWULFDOO\.ZWKHGLVVROXWLRQFRHIÀFLHQW
was calculated. Kw corresponds to the time when 63.2% of the
drug is dissolved.
The dissolution of pure ibuprofen in vitro at pH 5 showed
poor dissolution after 15 minutes and after 75 minutes. The
FRPSOH[HGGUXJKDGDVLJQLÀFDQWO\KLJKHUGLVVROXWLRQUDWHDQG
amount, due to the presence of the ћ-cyclodextrin. The dissolution rate of the complexed product was 0.086±0.002 min-¹,
the rate of pure ibuprofen was excluded from analysis since it
did not reach 63.2% within 72 minutes.The dissolved amount of
drug after 15 minutes was determined to be 71.9±3.62% for the
complexed prepared using the CPD method, and 22.0±3.56%
for pure drug. After 72 minutes, 93.5±2.89% of drug dissolved
from the ibuprofen-ћ-cyclodextrin complex and from pure
ibuprofen sample only 59.5±4.86% of drug dissolved. The comSOH[HGGUXJKDGDVLJQLÀFDQWLQFUHDVHLQDTXHRXVVROXELOLW\

Imatinib-Cyclodextrin

Imatinib, known as Gleevec, is an oral tablet or a capsule used
for the treatment of Philadelphia chromosome positive chronic
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myeloid leukemia (CML) or gastrointestinal stromal tumors.
Imatinib works by inhibiting protein tyrosine kinase, the growth
factor receptor that causes unregulated cell growth of cancer
cells (PubChem, 2005).
Aqueous solubility of imatinib is charge dependent and varies
depending on the pH. The active compound, imatinib, can be
mono, di, tri and tetra protonated. The more protonated the
compound the greater the overall charge of the compound.
Increased charge increases the aqueous solubility.At a pH below
5.5 the formation of different protonated species of imatinib
results in a charged drug that is water soluble. However, the free
base form of imatinib is neutral, uncharged, and therefore poorly
soluble. To increase the aqueous solubility of the free base form
of imatinib, the drug was complexed with ћ-cyclodextrin and
with randomly methylated ћ-cyclodextrin (RAMEB). Szabolcs
Beni, et al. performed a study determining the effectiveness of
cyclodextrin and cyclodextrin derivatives in increasing the solubility of the neutral drug form (Beni et. al. 2007).
In a solution of Na2CO3 at a pH of 10.5, 2 mg of imatinib
was added to a 1 ml solution of varying concentrations of ћ-cyclodextrin, 0-13 mM. The mixture was shaken for two days at
25.0 ± 0.5°C and a complexed product of 1:1 stoichiometry
was formed.
The aqueous solubility of the free base form of imatinib was
enhanced by complexing it with ћ-cyclodextrin. At a pH of 10
the linear AL phase solubility diagram indicated the improvement in the solubility of the drug. With increased cyclodextrin
concentration, the solubility of the drug increased linearly, complexation increased the drug solubility tenfold.
Titration of pure imatinib with KOH precipitated above a
pH of 6.5. Titration of 1mM imatinib in the presence of fourfold ћ-cyclodextrin or randomly methylated ћ-cyclodextrin
(RAMEB) did not precipitate due to the complex’s effect on
the solubility. The most stable form of the imatinib-cyclodextrin complex formed with the neutral form of imatinib. This is
because the neutral imatinib is most hydrophobic and interacts
most with the hydrophobic interior of the cyclodextrin. The afÀQLW\RILPDWLQLEWRZDUGVF\FORGH[WULQGHFUHDVHGDVWKHFKDUJH
on the drug increased.
ñ+ 105 FKHPLFDO VKLIW WLWUDWLRQ PHWKRG TXDQWLÀHG WKH
non-covalent molecular interactions. At a titration of pH 3.5 the
predominant imatinib species was the deprotonated form. The
mono and tri protonated forms were present in smaller quantities. Interactions between the imatinib forms and the ћ-cyclodextrin was evident. The data collected suggests that the benzamide fragment of imatinib is involved in the inclusion complex.
2D ROESY NMR spectra was recorded at the same pH to
verify the data. The evidence suggested that the imatinib inclusion proceeds through the narrower part of the cyclodextrin
host. For steric reasons the inclusion proceeds in an unusual
way, through the narrower part of the cyclodextrin. The result
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)LJXUH$/SKDVHVROXELOLW\GLDJUDP %HQLHWDO
of the study concluded that a tenfold increase in the imatinib
solubility was achieved with 12mM ћ-cyclodextrin complexation. The increased aqueous solubility of imatinib greatly increases the effectiveness of the anti-cancer drug.

of praziquantel the drug was complexed with ћ-cyclodextrin
and hydroxypropyl-ћ-cyclodextrin. A study was conducted to
determine whether this Class II drug can be complexed with cyclodextrin and behave like a Class I drug (Maragos et. al. 2009).
The praziquantel-cyclodextrin complexes were formed via
the kneading method. 0.080 grams of praziquantel was mixed
with cyclodextrin in varying ratios; 1:1, 1:2, and 1:4 molar ratios.
The complexed praziquantel-ћ-cyclodextrin reached equilibration within 12 hours and the praziquantel-hydroxypropyl-ћ-cyclodextrin complex reached equilibration after a 24 hour
period. Heating the samples at 70°C for an hour prior to the
experiment accelerated the reaction and also increased the formation of the praziquantel-cyclodextrin complex. The concentration of praziquantel in the binary system remained constant
while it was in a shaking bath at 25°C for 72 hours.

Praziquantel-Cyclodextrin

Praziquantel (PZQ) is a Class II drug, according to the BCS,
used for the treatment of schistosomiasis. The drug works by
causing severe spasm and paralysis to the worms’ muscles and
the worms are then destroyed in the intestines or passed in the
VWRRO,WLVFODVVLÀHGDVD&ODVV,,GUXJGXHWRLWVKLJKPHPEUDQH
permeability but low aqueous solubility. The low aqueous solubility is due to its lipophilic character (PubChem, 2005).
As a Class II drug, a high dose of praziquantel is necessary in
order for it to be effective. Improving the aqueous solubility of
SUD]LTXDQWHOFDQSRWHQWLDOO\UHVXOWLQWKHFODVVLÀFDWLRQRIWKHGUXJ
as a BCS-Class I compound. To increase the aqueous solubility

)LJXUH3URSRVHGLPDWLQLE&'FRPSOH[ %HQLHWDO

)LJXUH3KDVHVROXELOLW\GLDJUDPVRISUD]LTXDQWHO
ZLWKF\FORGH[WULQ 0DUDJRVHWDO
The aqueous solubility of the lipophilic drug had a 4-5-fold
increase upon complexation with cyclodextrin. Calculations
of the praziquantel solubility in 0.01 M cyclodextrin versus
the solubility of praziquantel without cyclodextrin calculated
a solubility enhancement factor of 4.5. Preheating the samples
at 70°C for one hour prior to the experiment increased the
solubility enhancement factor; a factor of 5.5 was calculated for
the praziquantel-ћ-cyclodextrin complex and 6.0 for the praziquantel-hydroxypropyl-ћ-cyclodextrin complex. Preheating the
sample before complexation enhanced the drug complexation
by increasing the dissolved amount of praziquantel that interacted with the cyclodextrin to form inclusion complexes.
The content of praziquantel in the product was determined
spectrometrically. The isoquinoline ring of the praziquantel inserted in the cyclodextrin cavity. The phase solubility diagrams
were linear. The praziquantel complexation was stronger with
ћ-cyclodextrin than with the hydroxypropyl-ћ-cyclodextrin
derivative as revealed by the complexation constants, K values,
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obtained from the diagram. Furthermore, the complexation enhancement as a result of preheating the sample was more significant in the hydroxypropyl-ћF\FORGH[WULQFRPSOH[DVUHÁHFWHG
in the K values.
Praziquantel complexation with different molar ratios of
cyclodextrin was studied. The praziquantel complex with
ћ-cyclodextrin had the highest drug concentration in a 1:2
praziquantel-cyclodextrin ratio. The optimum praziquantel-hydroxypropyl-ћ-cyclodextrin complex molar ratio was 1:4. The
different behaviors of the cyclodextrin derivatives are a result of
hydrogen bond formation between the drug and cyclodextrin.
After complexation with ћ-cyclodextrin and hydroxypropyl-ћ-cyclodextrin the drug was reevaluated in terms of the
BCS. The solubility/dose ratio, in relation to the dose and intestinal content, was calculated using solubility values of praziquantel in the presence and absence of ћ-cyclodextrin and
hydroxypropyl-ћ-cyclodextrin. At a low dose of 150 mg the
praziquantel complexed with ћ-cyclodextrin or hydroxypropyl-ћ-cyclodextrin had a higher solubility/dose ratio than pure
drug.The solubility was increased while the dose decreased.The
ORZGRVHIRUPRISUD]LTXDQWHOPJWKXVFODVVLÀHGDVD%&6
Class I drug.

Camptothecin-Cyclodextrin

camptothecin increased linearly with the increasing concentrations of various cyclodextrins. Camptothecin in the ћ-cyclodextrin complex had the highest increase in solubility, increasing
by about six-fold. њ-cyclodextrin increased the camptothecin
solubility three-fold and ќ-cyclodextrin increased the drug’s solXELOLW\ÀYHIROG2IWKHPRGLÀHGF\FORGH[WULQ5'0ћ-CD exhibited the greatest increase in camptothecin’s solubility. At 25%
weight / volume concentration of RDM-ћ-CD, the solubility of
camptothecin increased by a factor of 170. The methyl groups
VLJQLÀFDQWO\LQFUHDVHWKHVROXELOL]LQJHIIHFWRIWKLVF\FORGH[WULQ
derivative by disrupting the intramolecular hydrogen bonding
and enlarging the cyclodextrin cavity.

Conclusion
'UXJVROXELOLW\LVDQLPSRUWDQWIDFWRULQGHWHUPLQLQJWKHHIÀFDF\
of a drug. The low aqueous solubility of many pharmaceutical
developments is an area of constant research. This paper studied the effect of cyclodextrins on the solubility of poorly soluble
drugs. Cyclodextrins and their derivatives, by forming guesthost complexes, encapsulate an insoluble drug and increase its
aqueous solubility. The cyclodextrin carries the drug through
the aqueous solution and the complex dissociates upon reaching the site of action. The cyclodextrin drug carrier transports
WKHLQVROXEOHGUXJVZLWKRXWDOWHULQJWKHGUXJRUFDXVLQJVLJQLÀcant harm to the patient.
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